Trillium Asset Management LLC Decreases Position in Johnson & Johnson (NYSE:JNJ)

Trillium Asset Management LLC cut its stake in Johnson & Johnson (NYSE:JNJ) by 4.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 15,528 shares of the company’s stock after selling 731 shares during the quarter. Trillium Asset Management LLC’s holdings in Johnson & Johnson were worth $2,570,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently made changes to their positions in the stock. Atlantic Private Wealth LLC bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $32,000. 25 LLC bought a new position in shares of Johnson & Johnson in the first quarter worth approximately $55,000. Horizons Wealth Management boosted its position in shares of Johnson & Johnson by 1,730.0% in the second quarter. Horizons Wealth Management now owns 366 shares of the company’s stock worth $61,000 after purchasing an additional 346 shares during the period. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $66,000. Finally, Mcmillion Capital Management Inc. bought a new position in shares of Johnson & Johnson in the second quarter worth approximately $103,000. 68.40% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 0.9 %

NYSE JNJ opened at $149.91 on Tuesday. The company’s 50-day moving average price is $154.52 and its 200-day moving average price is $160.29. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. The stock has a market cap of $360.88 billion, a PE ratio of 11.13, a PEG ratio of 3.00 and a beta of 0.58. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $181.04.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, topping analysts’ consensus estimates of $2.52 by $0.14. The firm had revenue of $21.35 billion for the quarter, compared to analysts’ expectations of $21 billion. Johnson & Johnson had a net margin of 36.32% and a return on equity of 37.14%. Equities research analysts forecast that Johnson & Johnson will post 10.1 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 5th. Shareholders of record on Tuesday, November 21st will be issued a dividend of $1.19 per share. This represents a $4.76 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Monday, November 20th. Johnson & Johnson’s payout ratio is 35.34%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 26th. Raymond James lowered their target price on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a report on Wednesday, October 18th. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday. Barclays boosted their target price on shares of Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a report on Thursday, October 12th. Finally, Atlantic Securities upped their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a research note on Friday, August 4th. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $169.19.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.